TOKYO, Jun 09 (Pulse News Wire) – Ribomic INC. (4591.T) announced significant progress in its joint research with Tokyo University's Department of Ophthalmology aimed at developing aptamer-based therapies for eye diseases.
Key findings include RBM-006’s ability to inhibit intraocular pressure increase in glaucoma models and suppress pathological vascular growth in retinal disease models. Additionally, RBM-006 demonstrated anti-inflammatory effects against lipophosphatidylcholine-induced cytokine production in retinal pigment epithelial cells. These results indicate potential broad applicability across multiple ocular conditions such as glaucoma, age-related macular degeneration, and diabetic retinopathy.
The collaboration, initially set to conclude in July 2026, has been extended until March 2027 without additional costs. The extension supports RiboMics' strategic focus on expanding therapeutic applications and establishing unique mechanisms for differentiation, potentially enhancing licensing and partnership opportunities. There will be no impact on the fiscal year ending March 2027 due to the contract changes.
🟢 Confidence: High AI-translated content.